卵巢癌新辅助化疗期间常规静脉血栓栓塞预防的实施
该研究比较了卵巢癌新辅助化疗患者在接受常规血栓预防措施实施前后的静脉血栓栓塞(VTE)发生率。实施后VTE发生率从21.3%降至8.4%(p<0.01),且未增加大出血事件。多因素分析显示仅血栓预防与VTE风险降低显著相关(aOR 0.19;95%CI 0.07-0.53)。
要点
- 实施常规血栓预防后VTE发生率由21.3%降至8.4%(p<0.01)。
- 血栓预防与大出血事件无显著差异(0% vs 0.68%,p=0.63)。
- 多因素分析中仅血栓预防与VTE风险降低显著相关(aOR 0.19)。
核心结论
- 新辅助化疗期间常规血栓预防与整个主要治疗期间VTE风险降低相关,且不增加出血事件。
研究设计与样本
- 准实验前后对照研究,评估单一家医疗系统内2017年1月起实施常规血栓预防质量改进项目前后卵巢癌接受新辅助化疗患者的VTE发生率。
主要发现
- 实施前组136例中3.7%(n=5)接受血栓预防,实施后组154例中65.6%(n=101)接受血栓预防。
- 从化疗开始至治疗结束的总体VTE发生率:实施前组21.3%(n=29) vs 实施后组8.4%(n=13)(p<0.01)。
- 大出血事件两组无差异:实施前组0% vs 实施后组0.68%(p=0.63)。
- 单因素分析:血栓预防(OR 0.19;95%CI 0.07-0.52)和实施后时期(OR 0.34;95%CI 0.17-0.69)与主要治疗期间任何VTE风险降低相关。
- 多因素分析:仅血栓预防与VTE发生率降低显著相关(aOR 0.19;95%CI 0.07-0.53)。
关键数值与推荐
- 实施前组血栓预防接受率3.7%(n=5),实施后组65.6%(n=101)。
- VTE发生率:实施前组21.3%(n=29) vs 实施后组8.4%(n=13)(p<0.01)。
- 大出血事件:实施前组0% vs 实施后组0.68%(p=0.63)。
- 单因素分析:血栓预防OR 0.19(95%CI 0.07-0.52),实施后时期OR 0.34(95%CI 0.17-0.69)。
- 多因素分析:血栓预防aOR 0.19(95%CI 0.07-0.53)。
临床怎么用
- 研究提示新辅助化疗期间常规血栓预防与VTE风险降低相关,且未增加出血事件。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the venous thromboembolism (VTE) rate in patients with ovarian cancer undergoing neoadjuvant chemotherapy before and after implementing routine thromboprophylaxis. METHODS: This is a quasi-experimental pre-post study evaluating the VTE rate in patients with ovarian cancer who received neoadjuvant chemotherapy following a quality improvement initiative of routine thromboprophylaxis within a single healthcare system that started in January 2017. Patients were excluded if VTE was diagnosed before initiating chemotherapy. Patient factors and perioperative variables of interest were investigated for their association with VTE through univariate and multivariate models. RESULTS: Of the 136 patients in the pre-implementation group, 3.7% (n = 5) received thromboprophylaxis. Of the 154 patients in the post-implementation group, 65.6% (n = 101) received thromboprophylaxis. Provider compliance varied from 51% in 2019 to 79.3% in 2021. The overall rate of VTE, from the start of chemotherapy to the end of treatment, was 21.3% (n = 29) pre- and 8.4% (n = 13) in the post-implementation group (p < 0.01). There was no difference in major bleeding events between groups (0% vs. 0.68%, p = 0.63). On univariate analysis, thromboprophylaxis (OR 0.19; 95% CI 0.07-0.52) and post-implementation period (OR 0.34; 95% CI 0.17-0.69) were associated with a decreased risk of any VTE during primary treatment. On multivariate analysis, only thromboprophylaxis remained significantly associated with reduced VTE rates (aOR 0.19; 95% CI 0.07-0.53). CONCLUSION: Routine thromboprophylaxis during neoadjuvant chemotherapy is associated with reduced risk of VTE throughout primary treatment and is not associated with increased bleeding events.
引用
- McLaughlin HD, Greco P, Straubhar AM, et al. Implementation of routine venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2023. PMID: 37832182. doi:10.1016/j.ygyno.2023.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。